The design
The university describes a BPTI-derived synthetic peptide engineered for plasmin resistance. Its listing reports stability after 48 hours in the specified incubation assay and reduced ascites in xenograft models relative to BPTI. Oncology and hemostasis uses are proposed applications.
The intended action is durable plasmin inhibition. Fusion to tumor-targeting moieties and surgical hemostasis are proposed use cases, not demonstrated deployments.
Evidence described publicly
The disclosure reports an incubation stability comparison and preclinical xenograft observations. It does not provide a full peer-reviewed experimental report for the claimed applications.
- Plasmin resistance is reportedUC Davis reports resistance to degradation after 48 hours of plasmin incubation in its described assay.Source (external link)
- Ascites result is preclinicalThe listing reports a xenograft-model comparison against BPTI, not a clinical outcome.Source (external link)
- Patent pendingThe technology page gives patent-pending status without a published application number.Source (external link)
Record and status
The public listing does not provide a published application number.
A technology-transfer description with reported preclinical observations. No human therapeutic or surgery benefit is established.
Read the official patent or technology record (external link)